10-K: Structure Therapeutics Advances Obesity Pipeline, Secures $100M License

Structure Therapeutics Inc. reports significant progress in its obesity and metabolic disease pipeline, including positive Phase 2b data for aleniglipron and a $100 million non-exclusive license agreement.

Summary

• Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company focused on developing novel oral small molecule therapeutics for a wide range of chronic diseases, leveraging its structure-based drug discovery platform.
• The lead product candidate, aleniglipron (GSBR-1290), an oral selective GLP-1R agonist, is in five ongoing clinical studies for obesity, overweight, and related conditions.
• The Phase 2b ACCESS study for aleniglipron demonstrated a placebo-adjusted mean weight loss of 11.3% with the 120 mg dose at 36 weeks.
• The exploratory ACCESS II study showed a placebo-adjusted mean weight loss of 15.3% with the 240 mg dose at 36 weeks.
• A lower starting titration dose of 2.5 mg in the ACCESS Open Label Extension (OLE) and Body Composition studies significantly improved tolerability, with no adverse event-related discontinuations at the initial 2.5 mg or subsequent 5 mg dose.
• Aleniglipron also demonstrated clinically meaningful improvements in systolic blood pressure (-6.4 to -7.5 mmHg) and hemoglobin A1c (HbA1c) (-0.28% to -0.37%).
• The company has two oral small molecule amylin receptor agonists: ACCG-2671, currently in Phase 1 clinical development, and ACCG-3535, selected as a second development candidate, both showing promising preclinical data.
• Net loss for the year ended December 31, 2025, was $141.2 million, an increase from $122.5 million in 2024, contributing to an accumulated deficit of $470.3 million.
• Research and development expenses increased by 107% to $225.3 million in 2025, primarily due to increased clinical trial costs, preclinical R&D, personnel, and a $9.0 million milestone payment to Schrdinger.
• General and administrative expenses rose by 25% to $61.6 million in 2025, driven by increased headcount and public company operational costs.
• The company received $100.0 million in other license income from Genentech, Inc. and F. Hoffmann-La Roche Ltd (GNE) for a non-exclusive license of certain GLP-1 receptor agonist patents, distinct from aleniglipron.
• A $10.2 million gain was recognized from the sale of early-stage non-metabolic and non-obesity assets under the Exelixis Agreement.
• As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $1,446.2 million, which is expected to fund projected operations and key clinical milestones through the end of 2028, excluding pre-commercialization activities.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, driven by compelling Phase 2b clinical data for aleniglipron, significant capital raises, and a valuable non-exclusive licensing deal, which collectively de-risk future development and provide substantial financial runway.

Positives

• Reported strong Phase 2b ACCESS study results for aleniglipron, demonstrating a placebo-adjusted mean weight loss of 11.3% with the 120 mg dose at 36 weeks.
• Exploratory ACCESS II study showed even higher efficacy, with a placebo-adjusted mean weight loss of 15.3% at the 240 mg dose at 36 weeks.
• Improved tolerability was observed with a lower 2.5 mg starting titration dose in the ACCESS OLE and Body Composition studies, resulting in no AE-related treatment discontinuations at the initial 2.5 mg or subsequent 5 mg dose.
• Aleniglipron demonstrated clinically meaningful improvements in systolic blood pressure (-6.4 to -7.5 mmHg) and HbA1c (-0.28% to -0.37%).
• A compelling safety profile for aleniglipron was observed across all studies, with no cases of drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation.
• Secured a significant $100.0 million non-refundable, non-creditable upfront payment from Genentech and Roche for a non-exclusive license of certain GLP-1 receptor agonist patents, validating the company's intellectual property.
• Recognized a $10.2 million gain from the sale of early-stage non-metabolic and non-obesity assets to Exelixis.
• The company's cash, cash equivalents, and short-term investments reached $1,446.2 million as of December 31, 2025, providing a substantial financial runway expected to fund operations through the end of 2028.
• Advancing two oral small molecule amylin receptor agonists (ACCG-2671 in Phase 1, ACCG-3535 selected as second candidate) with promising preclinical data, including 'Cagrilintide-like efficacy' for ACCG-2671.
• Manufacturing capacity of 6,000 tons/year of aleniglipron is sufficient to supply treatment to over 120 million patients per year, highlighting scalability.
• Successfully remediated a previously reported material weakness in internal control over financial reporting as of June 30, 2024.

Negatives

• Incurred significant net operating losses of $141.2 million in 2025, $122.5 million in 2024, and $89.6 million in 2023, leading to an accumulated deficit of $470.3 million.
• Expects to continue incurring significant and increasing operating losses for the foreseeable future.
• Will require substantial additional capital to finance operations, which may not be available on acceptable terms or at all, potentially forcing delays or termination of development programs.
• Most product candidates are in early stages of development (preclinical or discovery), with only five in early clinical development, indicating a long and uncertain path to commercialization.
• Experienced delays in the Phase 2a study for aleniglipron due to a data collection omission at a clinical site, impacting 24 of 40 enrolled participants.
• Adverse event-related treatment discontinuation rate in the Phase 2b ACCESS study ranged from 7.7% to 13.3% across all doses, with a mean of 10.4% across active arms.
• Common adverse events in aleniglipron studies were gastrointestinal-related (nausea, vomiting, diarrhea, decreased appetite, headache, dehydration, dizziness).
• Decided ANPA-0073 (APJ receptor agonist) was not suitable for selective weight loss, shifting focus to other discovery-stage APJ receptor agonists.
• Considering strategic alternatives for LTSE-2578, a Phase 2 ready program, which may indicate a deprioritization of internal development for this candidate.
• Reliance on third parties for manufacturing product candidates, with current active pharmaceutical ingredients (APIs) and drug product manufactured in China, exposes the company to geopolitical risks, trade restrictions, and potential sanctions (e.g., BIOSECURE Act).
• Does not have long-term supply agreements with third-party manufacturers, increasing supply chain risk.
• Highly dependent on its senior management team; the loss of key personnel could significantly harm the business.
• Subject to stringent and evolving U.S. and foreign data privacy and security laws (e.g., GDPR, CCPA, PIPL), which increase compliance costs and risks.
• Potential for tax authorities to challenge transfer prices or classify the company as a China resident enterprise, leading to unfavorable tax consequences.
• Headquarters and main research facility are located near San Francisco, California, increasing vulnerability to natural disasters like earthquakes and fires, with no comprehensive disaster recovery or business continuity plan in place.
• Does not maintain insurance for environmental liability or toxic tort claims.

Risks

• Limited operating history and significant operating losses since inception, with expectations of continued losses for the foreseeable future.
• Requirement for substantial additional capital to finance operations, which may not be available on acceptable terms or at all, potentially forcing delays, reductions, or termination of product development programs.
• The company's structure-based drug discovery platform is unproven in terms of commercial value, and there is no guarantee of developing successful product candidates.
• Early stage of development for most product candidates (only five in early clinical development, others preclinical/discovery), leading to a lengthy, expensive, and uncertain development process with a high failure rate.
• Results of prior clinical and preclinical studies are not necessarily predictive of future results, and interim data may change with more comprehensive review.
• Difficulties or delays in the commencement, completion, termination, or suspension of clinical studies due to factors like regulatory consensus, patient enrollment/retention, third-party performance, or adverse events.
• Serious adverse events, undesirable side effects, or unexpected properties of product candidates may be identified during development or after approval, leading to discontinuation, refusal of approval, or revocation of marketing authorizations.
• Lack of organizational experience in conducting later-stage clinical studies or submitting New Drug Applications (NDAs).
• Lengthy, time-consuming, expensive, and inherently unpredictable marketing approval processes by the FDA and applicable foreign authorities.
• FDA and other foreign equivalents may not accept data from clinical studies conducted outside the United States, causing development delays.
• International trade policies, including tariffs, sanctions, and trade barriers (e.g., BIOSECURE Act impacting Chinese biotechnology manufacturing companies), may adversely affect business, financial condition, and supply chain.
• Disruptions to the operations of regulatory agencies (FDA, SEC) caused by funding shortages, leadership changes, or staffing cuts could delay regulatory reviews and approvals.
• Reliance on third parties for the manufacture of product candidates for preclinical and clinical development, increasing the risk of insufficient quantities, unacceptable cost/quality, and non-compliance with cGMP regulations.
• Current and anticipated future dependence on third parties for manufacturing may adversely affect future profit margins and timely commercialization.
• Reliance on third parties to conduct, supervise, and monitor discovery research, preclinical studies, and clinical studies, with risks of delays or increased costs if third parties do not perform satisfactorily.
• Inability to realize anticipated benefits from existing or future collaboration agreements and strategic alliances, or difficulty in forming such collaborations.
• Substantial competition from major pharmaceutical and biotechnology companies, potentially leading to others discovering, developing, or commercializing products more successfully.
• Absence of a marketing and sales organization and lack of experience in commercializing products, requiring significant resource investment or reliance on third parties.
• Changes in political and economic policies or relations between China and the United States may affect business, financial condition, results of operations, and the market price of ADSs.
• Inability to obtain and maintain sufficient intellectual property protection for platform technologies and product candidates, or if the scope is not sufficiently broad, allowing competitors to develop similar products.
• Product liability lawsuits against the company could cause substantial liabilities and limit commercialization.
• Compromised information technology systems or data security incidents could lead to significant financial, legal, regulatory, business, and reputational harm.
• Loss of ability to operate in Australia or receive research and development tax credits could adversely affect business and results of operations.
• Risk of misconduct or other improper activities by employees, principal investigators, consultants, and commercial partners, including non-compliance with regulatory standards and insider trading.
• Strict price controls imposed by foreign governments may adversely affect revenues.
• Stringent and evolving U.S. and foreign laws, regulations, rules, industry standards, and contractual obligations related to data security and privacy, increasing compliance costs and risks.
• Tax risks associated with cross-border arrangements and activities between the company and its subsidiaries, including potential challenges to transfer prices or classification as a China resident enterprise.
• Limitations on the ability to use net operating loss carryforwards and certain other tax attributes due to ownership changes under Sections 382 and 383 of the Code.
• Significantly increased costs and management time required for operating as a U.S. publicly traded company.
• Shareholder rights under Cayman Islands law differ from those under U.S. law, potentially making it more difficult for shareholders to protect their interests.
• Provisions in the amended and restated memorandum and articles of association may prevent or frustrate attempts by shareholders to change management or acquire a controlling interest.
• The price of ADSs may be volatile, and investors could lose all or part of their investment.
• Risk that future audit reports may not be prepared by auditors subject to inspection by the Public Company Accounting Oversight Board (PCAOB), potentially leading to trading prohibitions under the Holding Foreign Companies Accountable Act (HFCA Act).
• Substantial future sales of ADSs could cause the market price to drop significantly.
• Adverse effects from earthquakes, fires, or other natural disasters, particularly given the lack of a comprehensive disaster recovery or business continuity plan and specific insurance for environmental liability.

Future Outlook

The company anticipates initiating its Phase 3 registrational program for aleniglipron in chronic weight management in the second half of 2026, following an End-of-Phase 2 meeting with the FDA. It expects to report topline 44-week data from the ACCESS II study in Q1 2026, and topline data from the Body Composition and ACCESS OLE studies, as well as results from a maintenance switching study and a Phase 2 study in T2DM, in the second half of 2026. Initial Phase 1 study results for ACCG-2671 and the initiation of a Phase 1 study for ACCG-3535 are also expected in the second half of 2026. The company projects its current cash, cash equivalents, and short-term investments of $1,446.2 million will be sufficient to fund operations and key clinical milestones through the end of 2028, excluding pre-commercialization activities. It expects to continue incurring significant operating losses as it expands its pipeline and seeks regulatory approvals, and plans to explore additional collaborations.

Management Comments

• We believe that aleniglipron has the potential to be a differentiated treatment for obesity and provide a strong foundation to advance into Phase 3 clinical development.
• The Company believes that the data from the ACCESS clinical program supports and informs the advancement to Phase 3 clinical development program in the second half of 2026.
• We believe that our lead oral small molecule amylin development candidate, ACCG-2671, has the potential to be the first-in-class oral small molecule amylin treatment option for obesity.
• We believe we are well-positioned to overcome the limitations of existing peptide therapies through the development of novel oral small molecule therapeutics via our differentiated technology platform and approach.
• We view the likelihood to be remote that our operations will fundamentally change, as to require our auditor to be located in China.

Industry Context

StockSavvy.ai notes that the obesity and metabolic disease market is a rapidly growing and highly competitive area, with a total addressable market exceeding $100 billion annually. The company's focus on oral small molecule GPCR agonists aims to address limitations of existing injectable peptide therapies, such as patient convenience, dosing stringency, and scalability, which are significant industry challenges. The GLP-1R agonist class, in particular, has seen immense interest and demand, leading to drug shortages for approved injectables like Wegovy and Zepbound. Structure Therapeutics' progress with aleniglipron positions it as a potential oral competitor in this lucrative market, while its amylin and dual/tri-incretin programs aim to capture additional market share and address broader indications beyond obesity, aligning with the industry trend towards combination therapies and expanded therapeutic applications. The $100 million non-exclusive license agreement with Genentech/Roche for a GLP-1R agonist patent class, distinct from aleniglipron, indicates the value of the company's intellectual property in this competitive space, even for non-core assets.

Comparison to Industry Standards

• Aleniglipron's placebo-adjusted mean weight loss of 11.3% (120 mg, 36 weeks) and 15.3% (240 mg, 36 weeks) compares favorably to existing GLP-1R agonists. For example, oral semaglutide (Rybelsus) typically shows weight loss in the range of 5-10% over a similar period, while injectable semaglutide (Wegovy) can achieve 15-17% weight loss. Tirzepatide (Mounjaro/Zepbound), a dual GLP-1/GIP agonist, has shown up to 20% weight loss. Structure Therapeutics' oral small molecule approach, if it can achieve comparable or superior efficacy with a differentiated safety/tolerability profile and improved convenience, could be highly competitive against current market leaders like Novo Nordisk (Wegovy, Rybelsus) and Eli Lilly (Zepbound).
• The company's development of oral small molecule amylin receptor agonists (ACCG-2671, ACCG-3535) aims for a 'first-in-class' oral treatment option, potentially competing with peptide-based amylin analogs like cagrilintide (in development by Novo Nordisk), which has shown significant weight loss in combination with semaglutide. Preclinical data showing 'Cagrilintide-like efficacy' for ACCG-2671 suggests strong potential.
• The company's manufacturing capacity of 6,000 tons/year of aleniglipron, sufficient for over 120 million patients annually, highlights a significant scalability advantage over peptide injectables, which have faced fill-finish and device capacity limitations.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently the subject of any material governmental investigation, private lawsuit, or other legal proceeding.
• May be involved in legal and regulatory proceedings or investigations concerning matters that arise in the ordinary course of business in the future, which could result in significant fines or penalties, impact reputation, and divert management attention.

Related Party Transactions

• Ramy Farid, President and Chief Executive Officer of Schrdinger, Inc., was a member of the company's board of directors until June 25, 2024, at which time he ceased being a related party.
• The company has existing collaboration agreements with Schrdinger, LLC (Lhotse-Schrdinger Agreement from October 2020 and Aconcagua-Schrdinger Agreement from November 2023) for discovery and development of small molecule modulators.
• Paid Schrdinger $3.2 million in 2024 and $0.3 million in 2023 for collaboration services.
• Paid $3.0 million to Schrdinger in 2025 for milestone payments under the Aconcagua-Schrdinger Agreement, with an additional $6.0 million paid in January 2026.
• Scientific advisory board agreements with physicians who are compensated in the form of ordinary shares or share options in addition to cash consideration, which may be subject to reporting requirements to regulatory authorities.

Stakeholder Impact

• Shareholders: Potential for significant capital appreciation due to positive clinical data and strong financial position, but also subject to dilution from frequent equity offerings and market volatility. Principal shareholders and management exert significant control.
• Employees: Benefits from equity incentive plans (options, RSUs, ESPP) designed to attract, retain, and motivate personnel. Growth in headcount is expected. Subject to risks of misconduct and compliance with labor laws.
• Customers/Patients: Development of novel oral small molecule therapeutics aims to provide more accessible and potentially differentiated treatment options for chronic diseases like obesity and type 2 diabetes.
• Suppliers/CMOs: Continued reliance on third-party manufacturers, particularly in China, introduces supply chain risks, geopolitical exposure, and compliance challenges. Efforts are underway to diversify manufacturing sources.
• Creditors: The company's strong cash position of $1,446.2 million provides a solid financial buffer, reducing immediate credit risk, despite ongoing operating losses and future capital requirements.
• Regulatory Authorities: The company is subject to extensive and evolving regulatory requirements in the U.S. and internationally, including those related to drug development, manufacturing, marketing, data privacy, and cybersecurity. Compliance efforts are ongoing and costly.

Next Steps

• Plan an End-of-Phase 2 meeting with the FDA to align on a Phase 3 registrational program for aleniglipron.
• Anticipate initiating the Phase 3 program for aleniglipron in chronic weight management in the second half of 2026.
• Expect to report topline 44-week data from the ACCESS II study in the first quarter of 2026.
• Expect to report topline data from the Body Composition study in the second half of 2026.
• Expect to report topline data from the ACCESS OLE study in the second half of 2026.
• Expect to report topline results from its maintenance switching study evaluating transition from injectable GLP-1RA to aleniglipron in the second half of 2026.
• Expect to report topline results from its Phase 2 randomized placebo-controlled study assessing aleniglipron in patients with obesity or overweight and type 2 diabetes mellitus in the second half of 2026.
• Expect to report initial Phase 1 study results for ACCG-2671 in the second half of 2026.
• Expect to initiate a Phase 1 study for ACCG-3535 in the second half of 2026.
• Continue to invest in and leverage its structure-based drug discovery platform.
• Pursue additional opportunities in chronic diseases, particularly metabolic, endocrine, and cardiovascular indications.
• Explore additional collaborations with third parties to strengthen platform capabilities and expand portfolio.
• Continue to contract in parallel with additional suppliers outside of China to diversify manufacturing of API and drug product.
• Continually evaluate manufacturing strategy to satisfy demand for registration studies and commercial products.
• Expects to declare additional amylin development candidates in the future.

Key Dates

Recommendation

The company's robust Phase 2b clinical trial results for aleniglipron, showing significant weight loss and a favorable safety profile, position it as a strong contender in the high-demand obesity market. The substantial capital raises and the $100 million licensing deal with Genentech/Roche provide a solid financial runway through 2028, significantly de-risking its ambitious Phase 3 development plans and pipeline expansion. While early-stage development and regulatory risks persist, the positive data and strengthened financial position warrant a strong buy recommendation for long-term investors.

Keywords

Obesity, GLP-1R agonist, Amylin receptor agonist, GPCR, Metabolic diseases, Type 2 Diabetes, Oral small molecule, Clinical stage, Biopharmaceutical, Drug discovery, SEC filing, 10-K, Structure Therapeutics, Aleniglipron, ACCG-2671, ACCG-3535, Phase 2b, Clinical trials, Pharmaceutical, Biotechnology, Drug development, Corporate governance, Financial results, Risk factors, Intellectual property, Capital raise, China operations, Regulatory approval, Weight loss, Cardiometabolic benefits